

Press Release



December 21, 2018
Stem Cell & Device Laboratory, Inc.
<http://scad-kyoto.com/>

SCAD, Inc. receives approval for the development of products and services derived from human blood and related cells

Stem Cell & Device Laboratory, Inc. (SCAD) has received the approval from Cabinet Office of Japan, as part of its National Strategic Special Zones initiative, to develop and commercialize products and services derived from human blood and related cells. Due to the strict Japanese laws regarding the use of blood-derived products, only a handful of companies have been granted such approval.

This certification will further expand SCAD's capabilities into the generation of disease-specific iPS cell lines and their application in the research, development, and commercialization of disease models and efficacy assays for the Japanese and overseas customers, who are engaged in the research and development of therapeutic options for the diseases where there remain significant unmet medical needs.

We are convinced that these efforts will strengthen our vision towards the realization of "a new society created by stem cells" by enabling the faster delivery of efficacious and safe medicines to patients.

About SCAD

SCAD is an innovative biotech company offering cell product and service innovations that accelerate drug discovery and development through the convergence of nanotechnology, micro-engineering, and stem cell technologies. SCAD is committed to the development, manufacturing and commercialization of the next generation of cells and cell devices based on iPS cell technologies. SCAD's proprietary technologies in nanofiber-based cell culturing allow the creation of 3D, multilayered microtissues that closely recapitulate native tissues through increasing levels of maturity and functionality. Our initial offering is centered on the SCAD-MT™ cardiomyocyte, a myocardial microtissue, but other types of tissues are expected to come to market soon. As a company, we strive towards the realization of "a new society created by stem cells" by enabling the faster delivery of efficacious and safe medicines to patients.

For more information

Stem Cell & Device Laboratory, Inc. (SCAD)
Management Section: Ms. Sonoko Chiaki
TEL: +81-75-744-1114; E-mail: scad.info@scad-kyoto.com